SCHEMBL18172341

SCHEMBL18172341

CCC(=O)c1ccc(OC(=O)CCC(N)C(=O)O)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.50
SMN1; SMN2 Q16637 5/20 0.46
ALDH1A1 P00352 3/20 0.46
RAB9A P51151 2/20 0.46
NPC1 O15118 1/20 0.46
ELANE P08246 1/20 0.46
ESR1 P03372 2/20 0.45
HIF1A Q16665 2/20 0.45
RECQL P46063 1/20 0.45
LTA4H P09960 2/20 0.44
MAPT P10636 4/20 0.41
HTT P42858 2/20 0.41
LMNA P02545 1/20 0.41
HSD17B10 Q99714 1/20 0.41
KDM4E B2RXH2 2/20 0.41
TDP1 Q9NUW8 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
GAA P10253 2/20 0.40
POLB P06746 1/20 0.39
ABCB1 P08183 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2266753 0.85 GRM6 (0.46) KMT2AALDH1A1LTA4HMAPTHTT
SCHEMBL2266748 0.85 GRM6 (0.46) KMT2AALDH1A1LTA4HMAPTHTT
SCHEMBL8064264 0.81 LTA4H (0.55) KMT2AALDH1A1LTA4HMAPT
SCHEMBL1810781 0.81 LTA4H (0.55) KMT2AALDH1A1LTA4HMAPT
SCHEMBL4230862 0.80 SLC1A5 (0.47) KMT2AALDH1A1LTA4HMAPTHTT
SCHEMBL20278607 0.79 KMT2A (0.60) KMT2ASMN1; SMN2ALDH1A1RAB9ANPC1
SCHEMBL27615557 0.78 LTA4H (0.44) ALDH1A1RAB9ANPC1ELANELTA4H
SCHEMBL1818825 0.77 LTA4H (0.55) KMT2ASMN1; SMN2ALDH1A1LTA4HMAPT
SCHEMBL9222833 0.77 PDE4B (0.58) KMT2AALDH1A1RAB9ANPC1LTA4H
SCHEMBL10425785 0.76 LTA4H (0.38) KMT2ASMN1; SMN2ALDH1A1ELANEESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3286182-A1 TETRAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS F. Hoffmann-La Roche AG (CH) 2018-02-28 EP disclosed
WO-2016169902-A1 TETRAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2016-10-27 WO disclosed